Contact Information
Research Team
NamePositionOfficePhoneEmail
Quan LIUPhD Student (Lab Representative)N22-2001+853 8822 2907
Puhua WUPost-doctoral FellowN22-2001+853 8822 2907puhuawu@um.edu.mo
Yaojun JUPhD StudentN22-2001+853 8822 2907
Qingpin XIAOPhD StudentN22-2001+853 8822 2907
Yan ZHOUPhD StudentN22-2001+853 8822 2907
Education
DPhilUniversity of Oxford (1996)
MPhilHong Kong Polytechnic (1992)
BScHong Kong Baptist College (1990)
Positions
2013-presentAssociate Professor, Faculty of Health Sciences, University of Macau
2011 – 2012DMPK Design Leader, AstraZeneca
2004 – 2011Associate Principal Scientist, AstraZeneca
2001 – 2004Senior Scientist, AstraZenenca
1996– 2001Research Chemist, Sirius Analytical Ltd.
Research Interests
  • Development of small molecule inhibitors targeting cancer metabolism and Alzheimer’s disease
  • Pharmacokinetic and chemical optimizations of drug candidates
  • High throughput compound profiling for supporting drug discovery
Representative Publications
  1. W. Zhang, Xiaohui Hu, W. Zhou, K.Y. Tam, Liquid Chromatography-Tandem Mass Spectrometry Method Revealed that Lung Cancer Cells Exhibited Distinct Metabolite Profiles upon the Treatment with Different Pyruvate Dehydrogenase Kinase Inhibitors, Journal of Proteome Research, 17(9):3012-3021.
  2. S.L. Zhang, Z. Yang, X. Hu, H. Chakravarty, K.Y. Tam, Anticancer effects of some novel dichloroacetophenones through the inhibition of pyruvate dehydrogenase kinase 1, European journal of pharmaceutical sciences, 123, 43-55, 2018.
  3. S.L. Zhang, Y. He, K.Y. Tam, Targeting cancer metabolism to develop human lactate dehydrogenase (hLDH)5 inhibitors, Drug discovery today, 23, 1407-1415, 2018.
  4. Z. Yang, K.Y. Tam, Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes, International Journal of Biological Sciences, 14, 204-216, 2018.
  5. X. Wu, J. Kosaraju, W. Zhou, K.Y. Tam, SLOH, a carbazole-based fluorophore, mitigates neuropathology and behavioral impairment in the triple-transgenic mouse model of Alzheimer’s disease, Neuropharmacology, 131, 351-363, 2018.
  6. W. Zhou, X. Hu, K.Y. Tam, Systemic clearance and brain distribution of carbazole-based cyanine compounds as Alzheimer’s disease drug candidates, Scientific Reports, 7, 16368, 2017.
  7. W. Zhang, S.L. Zhang, X. Hu, K.Y. Tam, Phenyl butyrate inhibits pyruvate dehydrogenase kinase 1 and contributes to its anti-cancer effect, European journal of pharmaceutical sciences, 110, 93-100, 2017.
  8. S.L. Zhang, W. Zhang, Z. Yang, X. Hu, K.Y. Tam, Synthesis and biological evaluation of (R)-3,3,3-trifluoro-2-hydroxy-2-methylpropionamides as pyruvate dehydrogenase kinase 1 (PDK1) inhibitors to reduce the growth of cancer cells, European journal of pharmaceutical sciences, 110, 87-92, 2017.
  9. Z. Yang, X. Hu, S. Zhang, W. Zhang, K.Y. Tam, Pharmacological synergism of 2,2-dichloroacetophenone and EGFR-TKi to overcome TKi-induced resistance in NSCLC cells, European Journal of Pharmacology, 815, 80-87, 2017.
  10. X. Wu, J. Kosaraju, W. Zhou, K.Y. Tam, Neuroprotective Effect of SLM, a Novel Carbazole-Based Fluorophore, on SH-SY5Y Cell Model and 3xTg-AD Mouse Model of Alzheimer’s Disease, ACS Chemical Neuroscience, 8, 676-685, 2017.
  11. X. Wu, J. Kosaraju, K.Y. Tam, SLM, a novel carbazole-based fluorophore attenuates okadaic acid-induced tau hyperphosphorylation via down-regulating GSK-3beta activity in SH-SY5Y cells, European journal of pharmaceutical sciences, 110, 101-108, 2017.
  12. J. Kosaraju, R.M.D. Holsinger, L. Guo, K.Y. Tam, Linagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Mitigates Cognitive Deficits and Pathology in the 3xTg-AD Mouse Model of Alzheimer’s Disease, Molecular Neurobiology, 54, 6074-6084, 2017.
  13. X. Hu, K.Y. Tam, Association of vancomycin with lipid vesicles, ADMET & DMPK, 5, 183, 2017.
  14. X. Hu, K.Y. Tam, Biomembrane mimics and their roles in anti-bacterial drug discovery, ADMET & DMPK, 5, 9, 2017.
  15. W. Zhou, X. Wu, J. Li, X. Hu, K.Y. Tam, Quantification of permanent positively charged compounds in plasma using one-step dilution to reduce matrix effect in MS, Bioanalysis, 8, 497-509, 2016.
  16. S.L. Zhang, W. Zhang, Q.P. Xiao, Z. Yang, X.H. Hu, Z.Y. Wei, K.Y. Tam, Development of dichloroacetamide pyrimidines as pyruvate dehydrogenase kinase inhibitors to reduce cancer cell growth: synthesis and biological evaluation, RSC Advance, 6, 78762-78767, 2016.
  17. S.L. Zhang, X. Hu, W. Zhang, K.Y. Tam, Unexpected Discovery of Dichloroacetate Derived Adenosine Triphosphate Competitors Targeting Pyruvate Dehydrogenase Kinase To Inhibit Cancer Proliferation, Journal of medicinal chemistry, 59, 3562-3568, 2016.
  18. Z. Yang, K.Y. Tam, Anti-cancer synergy of dichloroacetate and EGFR tyrosine kinase inhibitors in NSCLC cell lines, European Journal of Pharmacology, 789, 458-467, 2016.
  19. G.J. Peters, K.Y. Tam, ADME/DMPK in the development and use of tyrosine and serine-threonine kinase inhibitors, ADMET & DMPK, 4, 182-185, 2016.
  20. W. Zhang, S.L. Zhang, X. Hu, K.Y. Tam, Targeting Tumor Metabolism for Cancer Treatment: Is Pyruvate Dehydrogenase Kinases (PDKs) a Viable Anticancer Target?, International Journal of Biological Sciences, 11, 1390-1400, 2015.
  21. S.L. Zhang, X. Hu, W. Zhang, H. Yao, K.Y. Tam, Development of pyruvate dehydrogenase kinase inhibitors in medicinal chemistry with particular emphasis as anticancer agents, Drug discovery today, 20, 1112-1119, 2015.
  22. X. Wu, J. Li, W. Zhou, K.Y. Tam, Animal models for Alzheimer’s disease: a focused review of transgenic rodent models and behavioral assessment methods, ADMET & DMPK, 3, 242-253, 2015.
  23. J. Li, W. Zhou, X. Wu, K.Y. Tam, Chemical and Physical Approaches for the Treatment of Alzheimer’s Disease, ADMET & DMPK, 3, 216-234, 2015.
  24. D. Dohoda, K. Tsinman, O. Tsinman, H. Wang, K.Y. Tam, Spectrophotometric pKa determination of ionizable pharmaceuticals: Resolution of molecules with weak pH-dependent spectral shift, Journal of pharmaceutical and biomedical analysis, 114, 88-96, 2015.
  25. M. Velicky, K.Y. Tam, RA. Dryfe, Mechanism of ion transfer in supported liquid membrane systems: electrochemical control over membrane distribution, Analytical chemistry, 86, 435-442, 2014.
  26. S.L. Zhang, H. Yao, C. Wang, K.Y. Tam, Study the interactions between human serum albumin and two antifungal drugs: fluconazole and its analogue DTP, Bioorganic & medicinal chemistry letters, 24, 4963-4968, 2014.
  27. W. Zhang, C. Wang, K.Y. Tam, Predicting the minimal inhibitory concentration of fluoroquinolones for Escherichia coli using an accumulation model, Bio-medical materials and engineering. 24, 3745-3751, 2014.
  28. K.Y. Tam, Estimating the “First in human” dose – a revisit with particular emphasis on oncology drugs, ADMET & DMPK, 1, 63-75, 2013.
  29. K.Y. Tam, The Roles of Doxorubicin in Hepatocellular Carcinoma, ADMET & DMPK, 1, 29-44, 2013.
  30. K.Y. Tam, Close relationships between in vitro ADMET and DMPK researches in pre-clinical drug discovery, ADMET & DMPK, 1, 1-2, 2013.
Full Publications List
Research Grants
2018-2021Development of metabolic inhibitor for the treatment of non-small-cell lung carcinoma, MOP 1,460,000
2017-2020Novel Multi-targeting compounds for the treatment of Alzheimer´s disease, MOP 540,000
2015-2018Combination treatment with arginine depleting enzyme and metabolic inhibitor in preclinical cancer models, MOP 1,500,000
2014-2017Preclinical optimization of Aβ peptides aggregation inhibitors as potential drug candidates for the treatment of Alzheimer’s disease, MOP 1,456,000
2013-2015A study of the interactions between vancomycin, nafcillin and biomimetic artificial membranes, MOP 125,000
Patents
  • S.C. Tsang, K.Y. Tam, X. Gao, “Composite Nanoparticles”, PCT WO2005007284, 27th Jan 2005.
Awards
2009AstraZeneca Regional Innovation Award
2008AstraZeneca Publication Award
Professional Recognition
2013Editor-in-chief, ADMET & DMPK (Scopus and ESCI indexed open access journal)
2009AstraZeneca Regional Innovation Award (for the contribution to a discovery project using a pro-drug delivery approach)
2008AstraZeneca Publication Award (Cancer and Infection Chemistry)
2004Fellow of the Royal Society of Chemistry, UK
1999Chartered Chemist and member of the Royal Society of Chemistry, UK